The most commonly reported adverse events associated with MYOBLOC™ treatment in all studies were **dry mouth, difficulty swallowing, impaired digestion and injection site pain.**

**Less common adverse events:** allergic reaction, fever headache related to injection, chest pain, chills, hernia, malaise, abscess, cyst, neoplasm, viral infection, arthritis, joint disorder, migraine, trouble breathing, lung disorder, pneumonia, anxiety, tremor, hypersensitive skin, sleepiness, confusion, pain related to neck spasm, vertigo, skin redness, gastrointestinal disorder, vomiting, tongue inflammation, mouth and gum inflammation, tooth disorder, itchiness, urinary tract infection, bladder infection, vaginal fungus infection, visual disturbance, ear infection, taste perversion, ringing of the ears, limb swelling, hypercholesterolemia, bruising.

Co-administration of MYOBLOC™ and aminoglycosides (certain antibiotics) or other agents interfering with neuromuscular transmission (i.e. curare-like compounds) should be performed with caution because the effect of the toxin may be increased.

The effect of administering different botulinum neurotoxin serotypes at the same time, or within less than four months of each other, is unknown. However, neuromuscular paralysis may be potentiated by co-administration or overlapping administration of different botulinum toxin serotypes.